Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Q2 2021 vs. Q1 2021
How the institutions holding Ambrx Biopharma, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 0 | 20 | +20 |
| Shares | 0 | 13.9M | +13.9M |
| Value | $0 | $266.2M | +$266.2M |
New holders (20)
Institutions that held Ambrx Biopharma, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 3,766,940 | $68.7M | 0.01% |
| Cormorant Asset Management, LP | 2,486,386 | $47.0M | 1.83% |
| Fosun International Ltd | 1,932,591 | $37.9M | 2.25% |
| Adage Capital Partners GP, L.L.C. | 1,827,292 | $35.8M | 0.07% |
| Suvretta Capital Management, LLC | 1,169,529 | $22.9M | 0.34% |
| BlackRock Inc. | 850,676 | $16.7M | 0.00% |
| Artal Group S.A. | 850,000 | $16.7M | 0.38% |
| Octagon Capital Advisors LP | 450,000 | $8.82M | 1.83% |
| Millennium Management LLC | 144,092 | $2.82M | 0.00% |
| Monashee Investment Management LLC | 110,000 | $2.16M | 0.26% |
| Alliancebernstein L.P. | 70,000 | $1.37M | 0.00% |
| Norges Bank | 70,000 | $1.37M | 0.00% |
| Tudor Investment Corp Et Al | 60,000 | $1.18M | 0.02% |
| Caas Capital Management LP | 40,000 | $784.0K | 0.04% |
| Ghisallo Capital Management LLC | 40,000 | $784.0K | 0.03% |
| Marshall Wace North America L.P. | 32,648 | $640.0K | 0.00% |
| Parkman Healthcare Partners LLC | 15,000 | $294.0K | 0.06% |
| Boothbay Fund Management, LLC | 13,422 | $263.0K | 0.01% |
| Pinz Capital Management, LP | 1,000 | $20.0K | 0.01% |
| Bank of America Corp | 110 | $2.00K | 0.00% |
Sold out (0)
Institutions that held Ambrx Biopharma, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
None.